Hudson Bay Capital Management
BRNS

Hudson Bay Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

Hudson Bay Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-41,599
Closed -$462K – 1204
2021
Q4 		$462K Sell
41,599
-147,702
-78% -$1.86M ﹤0.01% 860
2021
Q3 		$2.96M Hold
189,301
– – 0.04% 529
2021
Q2 		$3.1M Buy
+189,301
New +$2.8M 0.04% 492

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return

Hudson Bay Capital Management's BRNS Position: Q1 2022 in Review

Hudson Bay Capital Management sold out of Barinthus Biotherapeutics (BRNS) in Q1 2022, closing a stake of 41,599 shares — an estimated $462K sold.

Hudson Bay Capital Management first reported a position in BRNS in Q2 2021 and held it in 3 quarters. The position peaked at $3.1M in Q2 2021. 12 funds tracked by Wall St. Rank hold BRNS as of Q1 2022.

  • Hudson Bay Capital Management reported no remaining Barinthus Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 41,599 Barinthus Biotherapeutics shares in Q1 2022, an estimated $462K.
  • Hudson Bay Capital Management first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • Hudson Bay Capital Management's Barinthus Biotherapeutics position peaked at $3.1M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2022.

Based on Hudson Bay Capital Management's 13F filing for Q1 2022, filed 16 May 2022.